Dr. Corbett is interviewed in Issue 17 of CuraLink, the Cura Foundation’s newsletter.
As SARS-CoV-2 swept the globe, Dr. Corbett and her team at the Vaccine Research Center at the National Institutes of Health rushed to design an effective vaccine against it. Just 66 days after the viral sequence was released, her team rapidly deployed the concept to industry partner Moderna for a Phase 1 clinical trial. The vaccine was shown to be 94.1% effective in Phase 3 clinical trials and went on to prevent severe disease and death for hundreds of thousands of people worldwide. Every step of the way, Dr. Corbett leveraged science for the public good—building trust in communities of color and combating misinformation on the national stage. She continually looks at the “bigger picture” beyond her lab and reminds each of us to use our talents to benefit all. Now, at Harvard T.H. Chan School of Public Health, Dr. Corbett will continue to propel novel vaccine development for pandemic preparedness. The COVID-19 emergency may be over, but the legacy of Dr. Kizzmekia Corbett will live on. Read the full interview on the CuraLink website.